1-3 of 3
Howard A. Burris, Sr.
Close
Sort by
Journal Articles

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Camille Abboud, Sr., Jan Maciej Zaucha, Scott R. Solomon, Terrence Bradley, Elie Mouhayar, Noemi Angelosanto, Hendrik Nogai, Renata Dudziak, Tomasz Rzymski, Peter Littlewood, Krzysztof Brzózka, Axel Glasmacher, Gautam Borthakur, Howard A. Burris, Sr., Ewa Lech Marańda
Journal: Blood
Blood (2022) 140 (Supplement 1): 6228–6229.
https://doi.org/10.1182/blood-2022-163150
Published: 2022
Journal Articles

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

Tomasz Rzymski, Urszula Pakulska, Camille Abboud, Sr., Howard A. Burris, Sr., Scott R. Solomon, Marta Obacz, Kristina Goller, Michal Combik, Jan Zaucha, Milena Mazan, Michal Mikula, Magdalena Cybulska, Anna Polak, Przemyslaw Juszczynski, Marcus Järås, Marion Chapellier, Johan Flygare, Magdalena Zawadzka, Karolina Bukowska Strakova, Krzysztof Brzozka, Setareh Shamsili, Noemi Angelosanto
Journal: Blood
Blood (2021) 138 (Supplement 1): 2371.
https://doi.org/10.1182/blood-2021-152273
Published: 2021
Journal Articles

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Camille Abboud, Sr., Gautam Borthakur, Scott R. Solomon, Howard A. Burris, Sr., Terrence Bradley, JAN Maciej Zaucha, Sr., Ewa Lech-Marańda, Krzysztof Brzozka, Tomasz Rzymski, Peter Littlewood, Elie Mouhayar, Setareh Shamsili, Noemi Angelosanto
Journal: Blood
Blood (2021) 138 (Supplement 1): 3418.
https://doi.org/10.1182/blood-2021-151030
Published: 2021